-
ALSO READ
Covid-19 crisis: Bharat Biotech's vaccine gets nod for human trials
Repurposing capacity for Covid-19 vaccine, say Indian pharma firms
Indian samples of global Covid-19 vaccines need to be larger: Experts
Covid-19 crisis: Race to develop vaccine gets a booster as field widens
Coronavirus vaccine update: Bharat Biotech starts human trial at PGI-Rohtak
-
Bharat Biotech has admitted that in August, there was an adverse event during the Phase-1 clinical trials of its Covid-19 vaccine.
The firm said subject was now safe. Though it was reported to the drug regulator within 24 hours, the event turned out to be unrelated to the vaccine.
“The adverse event was investigated, and presented to the CDSCO-DCGI, prior to obtaining permission for Phase-2 and Phase-3 trials," it said.
The firm is now conducting Phase-3 trials and the event will have no impact on timelines.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU